Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Redmond

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Expert Opinion on Biological Therapy|August 17, 2023
Challenges and opportunities in the development of combination immunotherapy with OX40 agonistsWilliam L Redmond
Current Oncology Reports|March 30, 2022
Current Clinical Trial Landscape of OX40 AgonistsRashi Yadav, William L Redmond
Immunological Investigations|October 27, 2022
A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral BloodYoshinobu Koguchi, William L Redmond
Oncoimmunology|January 15, 2025
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapyKengo Tanigawa, William L Redmond
Oncoimmunology|July 23, 2014
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its partsStefanie N Linch, William L Redmond
Human Vaccines & Immunotherapeutics|July 27, 2016
Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8<sup>+</sup> T cellsWilliam L Redmond, Stefanie N Linch
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 12, 2018
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell AgonistsDana A Emerson, William L Redmond
Critical Reviews in Immunology|January 17, 2008
Targeting OX40 and OX40L for the treatment of autoimmunity and cancerWilliam L Redmond, Andrew D Weinberg
Journal for Immunotherapy of Cancer|June 23, 2016
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapyStefanie N Linch, William L Redmond
Immunity|March 23, 2005
Peripheral tolerance of CD8 T lymphocytesWilliam L Redmond, Linda A Sherman
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Expert Opinion on Biological Therapy|August 17, 2023
Challenges and opportunities in the development of combination immunotherapy with OX40 agonistsWilliam L Redmond
Current Oncology Reports|March 30, 2022
Current Clinical Trial Landscape of OX40 AgonistsRashi Yadav, William L Redmond
Immunological Investigations|October 27, 2022
A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral BloodYoshinobu Koguchi, William L Redmond
Oncoimmunology|January 15, 2025
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapyKengo Tanigawa, William L Redmond
Oncoimmunology|July 23, 2014
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its partsStefanie N Linch, William L Redmond
Human Vaccines & Immunotherapeutics|July 27, 2016
Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8<sup>+</sup> T cellsWilliam L Redmond, Stefanie N Linch
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 12, 2018
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell AgonistsDana A Emerson, William L Redmond
Critical Reviews in Immunology|January 17, 2008
Targeting OX40 and OX40L for the treatment of autoimmunity and cancerWilliam L Redmond, Andrew D Weinberg
Journal for Immunotherapy of Cancer|June 23, 2016
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapyStefanie N Linch, William L Redmond
Immunity|March 23, 2005
Peripheral tolerance of CD8 T lymphocytesWilliam L Redmond, Linda A Sherman
Pageof 7